No Picture
News

Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

– Phesgo® Can be Administered in 5 to 8 Minutes Compared with Hours for the Standard Sequential IV Administration of Perjeta® and Herceptin® — First Subcutaneous Fixed-dose Combination of Two Monoclonal Antibodies Approved in Europe Utilizing Halozyme… […]

No Picture
News

Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021

Approximately 25 Million Adult Women Covered by Medicaid

SAN DIEGO, Dec. 22, 2020 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS)… […]

No Picture
News

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today an… […]

No Picture
News

V2ACT Therapeutics(TM), LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer

– V2ACT Therapeutics(TM), LLC is a joint venture of Genelux Corporation and TVAX Biomedical, Inc.- V2ACT is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic immunotherapy) and V-ACT (vaccine-enhanced adoptive cell therapy).- V2ACT… […]

No Picture
News

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

– Tolperisone was comparable to placebo on driving performance; cyclobenzaprine, market leading skeletal muscle relaxant, was significantly worse at all time points- Tolperisone similar to placebo on three measures of sleepiness whereas cyclobenzaprine… […]

No Picture
News

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

– Tolperisone was comparable to placebo on driving performance; cyclobenzaprine, market leading skeletal muscle relaxant, was significantly worse at all time points- Tolperisone similar to placebo on three measures of sleepiness whereas cyclobenzaprine… […]